Group issues guidelines for diagnosing, treating NAFLD and NASH | Studies link moderate drinking to greater AFib risk | Midlife physical activity may protect against dementia
Web Version
July 15, 2014
AANP SmartBrief
News for nurse practitioners

Health Care NewsAdvertisement
Group issues guidelines for diagnosing, treating NAFLD and NASH
Clinicians should screen for nonalcoholic steatohepatitis in patients with hypertension, type 2 diabetes, sleep apnea, a family history of NASH, a sedentary lifestyle, obesity or hyperlipidemia, according to guidelines from the World Gastroenterology Organisation. The group also cautions against treating all nonalcoholic fatty liver disease and NASH patients aggressively, and suggests first prescribing diet and exercise. Experimental therapies may be appropriate in patients who fail to achieve adequate weight loss, the group says. Medscape (free registration) (7/11)
Share: LinkedInTwitterFacebookGoogle+Email
Studies link moderate drinking to greater AFib risk
A study published in the Journal of the American College of Cardiology showed that even moderate daily consumption of wine or liquor, but not beer, was associated with a higher risk of developing atrial fibrillation. The risk of developing irregular heartbeat rose 8% for each additional drink of any kind of alcohol per day, an analysis of data from six studies found. HealthDay News (7/14)
Share: LinkedInTwitterFacebookGoogle+Email
Midlife physical activity may protect against dementia
Seniors and older adults who were physically active in middle age had a lower risk of developing Alzheimer's disease and other forms of dementia, according to two studies presented at the Alzheimer's Association International Conference. HealthDay News (7/14)
Share: LinkedInTwitterFacebookGoogle+Email
Risk factors for sleep-related death differ for younger, older infants
A study in the journal Pediatrics found that 74% of infants aged 3 months and younger who died during sleep were sharing a bed with an adult at the time. For older infants, the strongest risk factor for sleep-related death was rolling into objects placed in the sleeping area. USA Today (7/14), (7/13)
Share: LinkedInTwitterFacebookGoogle+Email
Obese dysglycemic youths show progressive decline in glucose sensitivity
Obese youths with impaired glucose tolerance and type 2 diabetes showed lower and progressively deteriorating glucose sensitivity similar to that of adult dysglycemia compared with those who had normal glucose tolerance, a study in Diabetes indicated. News (7/11)
Share: LinkedInTwitterFacebookGoogle+Email
Free Patient Resource
Take action TODAY and visit to download or order the free Handbook for People with Pain—a patient resource for those who suffer with pain.

Also available in Spanish.
Pharmaceutical News
Measurement type affects dosing errors in child medications
Parents who used a teaspoon or a tablespoon to measure doses of child medication had a twofold increased risk of making a dosing error compared with those who measured the medication in milliliters, a study in the journal Pediatrics showed. Among the 287 parents included in the study, 39% made an error in measuring out the dose, while 41% made a did not know the correct prescribed dose. (7/13), HealthDay News (7/14)
Share: LinkedInTwitterFacebookGoogle+Email
Linezolid may raise hypoglycemia risk in diabetes
An FDA review found a correlation between linezolid use and hypoglycemic events in diabetes patients, with the highest risk seen in those taking insulin or oral hypoglycemic agents. The review was published in Clinical Infectious Diseases. Healio (free registration)/Infectious Disease News (7/11)
Share: LinkedInTwitterFacebookGoogle+Email
Analysis: Diabetes drug lowers dementia risk
Seniors taking the diabetes drug pioglitazone, known better by its branded name, Actos, had significantly reduced odds of dementia onset with every additional three months it was prescribed, German researchers noted. The results of the analysis were presented at the Alzheimer's Association International Conference. Reuters (7/14)
Share: LinkedInTwitterFacebookGoogle+Email
Emerging Trends, Products and Technologies
NP's app helps identify hypertension risk in children
A free smartphone application named Pedia BP helps clinicians determine pediatric patients who are at risk of hypertension. The app has been downloaded by about 10,000 users and incorporates complex tables developed by the CDC and the National High Blood Pressure Education Program Working Group on Adolescents and Children. It is "easier to use, improves accuracy of results, simplifies the process, and saves time," said nurse practitioner Hope Bussenius, who designed the tool. (7/10)
Share: LinkedInTwitterFacebookGoogle+Email
Health Policy and Legislative News
Medicaid, CHIP add 6.7M enrollees under ACA
CMS officials said Friday that 6.7 million new enrollees gained Medicaid or Children's Health Insurance Program coverage from September to May. Twenty-six states and Washington, D.C., opted to expand Medicaid, and they had a 17% increase in enrollment rates. Children are 56% of the programs' enrollees, "highlighting the importance of these programs to the health and well-being of our nation's children," said CMS Deputy Administrator Cindy Mann. The Hill (7/11)
Share: LinkedInTwitterFacebookGoogle+Email
Conn. and Minn. reduce barriers to full practice
New laws in Connecticut and Minnesota have reduced the need for advanced practice registered nurses to have collaborative agreements. "We will continue to work as hard as we can for nurse practitioners to get the full scope authority. There is a lot of support coming from the public," AANP President Ken Miller said. (7/9)
Share: LinkedInTwitterFacebookGoogle+Email
CE article provides pharmacology credits
The July issue of JAANP includes a CE article on sodium glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. This new class of oral medications includes two FDA-approved drugs, dapagliflozin and canagliflozin, has a unique, insulin-independent mechanism of action and provides an alternative to other drugs in combination therapy, or as monotherapy in selected patients unable to tolerate other first-line options. The added benefits of weight loss, blood pressure reduction and improvements in lipid parameters are likely to make this new drug class a focus of intense research in the future.
Share: LinkedInTwitterFacebookGoogle+Email
No person was ever honored for what he received. Honor has been the reward for what he gave."
-- Calvin Coolidge,
30th U.S. president
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AANP ->Home Page | Join AANP | Legislation/Practice | CareerLink | AANP Store
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tom Parks
Advertising:  Aaron Kern
  P: 202.407.7866

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information